These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 9378691)

  • 21. Efficacy and tolerability of premenstrual use of venlafaxine (flexible dose) in the treatment of premenstrual dysphoric disorder.
    Cohen LS; Soares CN; Lyster A; Cassano P; Brandes M; Leblanc GA
    J Clin Psychopharmacol; 2004 Oct; 24(5):540-3. PubMed ID: 15349012
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intermittent versus continuous sertraline therapy in the treatment of premenstrual dysphoric disorders.
    Alpay FB; Turhan NO
    Int J Fertil Womens Med; 2001; 46(4):228-31. PubMed ID: 11563834
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Sertraline in the treatment of premenstrual dysphoric disorder].
    Culav-Sumić J; Skocilić Z; Jukić V
    Lijec Vjesn; 1999; 121(7-8):234-8. PubMed ID: 10573958
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of premenstrual dysphoric disorder with selective serotonin reuptake inhibitors.
    Luisi AF; Pawasauskas JE
    Pharmacotherapy; 2003 Sep; 23(9):1131-40. PubMed ID: 14524645
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pretreatment pattern of symptom expression in premenstrual dysphoric disorder.
    Pearlstein T; Yonkers KA; Fayyad R; Gillespie JA
    J Affect Disord; 2005 Apr; 85(3):275-82. PubMed ID: 15780697
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Selective serotonin reuptake inhibitors for premenstrual syndrome.
    Brown J; O' Brien PM; Marjoribanks J; Wyatt K
    Cochrane Database Syst Rev; 2009 Apr; (2):CD001396. PubMed ID: 19370564
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Weekly luteal-phase dosing with enteric-coated fluoxetine 90 mg in premenstrual dysphoric disorder: a randomized, double-blind, placebo-controlled clinical trial.
    Miner C; Brown E; McCray S; Gonzales J; Wohlreich M
    Clin Ther; 2002 Mar; 24(3):417-33. PubMed ID: 11952025
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Psychiatric and psychological aspects of premenstrual syndrome].
    Limosin F; Ades J
    Encephale; 2001; 27(6):501-8. PubMed ID: 11865558
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Time to relapse after short- or long-term treatment of severe premenstrual syndrome with sertraline.
    Freeman EW; Rickels K; Sammel MD; Lin H; Sondheimer SJ
    Arch Gen Psychiatry; 2009 May; 66(5):537-44. PubMed ID: 19414713
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Placebo-controlled trial comparing intermittent and continuous paroxetine in premenstrual dysphoric disorder.
    Landén M; Nissbrandt H; Allgulander C; Sörvik K; Ysander C; Eriksson E
    Neuropsychopharmacology; 2007 Jan; 32(1):153-61. PubMed ID: 17035933
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sertraline in the treatment of premenstrual dysphoric disorder.
    Yonkers KA; Halbreich U; Freeman E; Brown C; Pearlstein T
    Psychopharmacol Bull; 1996; 32(1):41-6. PubMed ID: 8927673
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A preliminary study of luteal phase versus symptom-onset dosing with escitalopram for premenstrual dysphoric disorder.
    Freeman EW; Sondheimer SJ; Sammel MD; Ferdousi T; Lin H
    J Clin Psychiatry; 2005 Jun; 66(6):769-73. PubMed ID: 15960573
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A double-blind, placebo-controlled study comparing the effects of sertraline versus amitriptyline in the treatment of major depression.
    Lydiard RB; Stahl SM; Hertzman M; Harrison WM
    J Clin Psychiatry; 1997 Nov; 58(11):484-91. PubMed ID: 9413414
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Response to sertraline is associated with reduction in anxiety-potentiated startle in premenstrual dysphoric disorder.
    Hantsoo L; Grillon C; Sammel M; Johnson R; Marks J; Epperson CN
    Psychopharmacology (Berl); 2021 Oct; 238(10):2985-2997. PubMed ID: 34292344
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Venlafaxine in the treatment of premenstrual dysphoric disorder.
    Freeman EW; Rickels K; Yonkers KA; Kunz NR; McPherson M; Upton GV
    Obstet Gynecol; 2001 Nov; 98(5 Pt 1):737-44. PubMed ID: 11704162
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Paroxetine controlled release for premenstrual dysphoric disorder: a double-blind, placebo-controlled trial.
    Cohen LS; Soares CN; Yonkers KA; Bellew KM; Bridges IM; Steiner M
    Psychosom Med; 2004; 66(5):707-13. PubMed ID: 15385695
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment of premenstrual dysphoric disorder with the GABA
    Bixo M; Ekberg K; Poromaa IS; Hirschberg AL; Jonasson AF; Andréen L; Timby E; Wulff M; Ehrenborg A; Bäckström T
    Psychoneuroendocrinology; 2017 Jun; 80():46-55. PubMed ID: 28319848
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Non-contraceptive oestrogen-containing preparations for controlling symptoms of premenstrual syndrome.
    Naheed B; Kuiper JH; Uthman OA; O'Mahony F; O'Brien PM
    Cochrane Database Syst Rev; 2017 Mar; 3(3):CD010503. PubMed ID: 28257559
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Is sertraline an effective therapy for premenstrual dysphoric disorder?
    Fernandes O; Por CP; Evans MF
    Can Fam Physician; 1998 Apr; 44():765-7. PubMed ID: 9585849
    [No Abstract]   [Full Text] [Related]  

  • 40. Selective serotonin reuptake inhibitors for premenstrual dysphoric disorder: the emerging gold standard?
    Pearlstein T
    Drugs; 2002; 62(13):1869-85. PubMed ID: 12215058
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.